Sign In
Buy TGTX
$40.11
+3.47 (+9.47%)
At Close: Jun 03, 2026
Biopharmaceutical Stock Soars on Earnings Beat
11:29am, Wednesday, 01'st Nov 2023
TG Therapeutics Inc (NASDAQ:TGTX) stock is soaring today, after the biopharmaceutical name's third-quarter results smashed analyst expectations.
TG Therapeutics to Host Conference Call on Third Quarter 2023 Financial Results and Business Update
07:30am, Monday, 30'th Oct 2023
Conference call to be held Wednesday, November 1, 2023, at 8:30 AM ET Conference call to be held Wednesday, November 1, 2023, at 8:30 AM ET
TG Therapeutics: Things Are Stacking Up Against Briumvi
04:47pm, Monday, 16'th Oct 2023
TG Therapeutics, Inc. stock has declined by 75% since its approval highs, with little hope of recovery. The company's fortunes have been tied to its earnings, with a Q2 miss causing a significant drop
TG Therapeutics (TGTX) stock price has plunged: buy the dip?
09:32am, Wednesday, 11'th Oct 2023
TG Therapeutics (NASDAQ: TGTX) stock price sell-off continued this week as concerns about the rising competition continued. The shares plunged to a low of $7.53 on Wednesday, much lower than the year-
TG Therapeutics: Racing Against Time While Their Differentiators Are Still Relevant
02:26pm, Tuesday, 03'rd Oct 2023
TG Therapeutics has transitioned from a developer of oncology drugs to a commercial-stage neurology company with the approval of its multiple sclerosis (MS) drug, Briumvi. Briumvi, the flagship drug o
TG Therapeutics to Participate in the 2023 Cantor Global Healthcare Conference
07:30am, Friday, 22'nd Sep 2023
Fireside chat scheduled for Tuesday, September 26, 2023, at 12:25 PM ET Fireside chat scheduled for Tuesday, September 26, 2023, at 12:25 PM ET
TG Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
07:30am, Thursday, 07'th Sep 2023
Fireside chat scheduled for Monday, September 11, 2023, at 10:30 AM ET Fireside chat scheduled for Monday, September 11, 2023, at 10:30 AM ET
3 Very Oversold Biotech Stocks to Buy Right Now
12:43am, Tuesday, 29'th Aug 2023
After I spent many years following Wall Street, there are a few characteristics about the “big money” that stand out for me. One of these traits is that many if not most large investors are very
Why Is TG Therapeutics (TGTX) Stock Down 50% Today?
12:56pm, Tuesday, 01'st Aug 2023
Following a disappointing outcome for the second quarter, shares of biotechnology firm TG Therapeutics (NASDAQ: TGTX ) suffered a catastrophic loss. Specializing in Briumvi — a therapeutic for the t
TG Therapeutics to Host Conference Call on Second Quarter 2023 Financial Results and Business Update
08:30am, Monday, 31'st Jul 2023
NEW YORK, July 31, 2023 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that a conference call will be held on Tuesday, August 1, 2023, at 8:30 AM ET to discuss results for t
TG Therapeutics: Addressing The SC Ocrevus Concern
09:50pm, Saturday, 29'th Jul 2023
The launch of Briumvi is off to a solid start, but the stock pulled back recently and fell more after Roche reported positive phase 3 results of subcutaneously administered Ocrevus. The improved conve
Down -12.63% in 4 Weeks, Here's Why You Should You Buy the Dip in TG Therapeutics (TGTX)
10:51am, Monday, 24'th Jul 2023
The heavy selling pressure might have exhausted for TG Therapeutics (TGTX) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street ana
Ocrevus Challenges Briumvi: A Closer Look At TG Therapeutics' Position
05:49pm, Thursday, 13'th Jul 2023
TG Therapeutics, Inc.'s Briumvi, a treatment for multiple sclerosis, faces competition from Roche's Ocrevus, which has shown positive results in a Phase 3 trial. Briumvi's intravenous administration c
How Roche Just Cut Top 1% Biotech Stock TG Therapeutics Down A Peg
09:23am, Thursday, 13'th Jul 2023
Roche unveiled positive results Thursday for a rival to TG Therapeutics' infusion for multiple sclerosis patients, and TGTX stock crashed.
TG Therapeutics: Recent Progress Of Briumvi Builds Up Momentum
07:06pm, Wednesday, 05'th Jul 2023
Partial sales of TG Therapeutics, Inc.'s BRIUMVI for Relapsing forms of multiple sclerosis reached $7.8 million in Q1 of 2023. In June 2023, TG Therapeutics received European approval of BRIUMVI for r
